HER2 Support Group Forums - View Single Post - XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281

Rich66 · 12-13-2008, 08:27 PM

Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs

Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase

full article:
http://online.wsj.com/article/SB1229...googlenews_wsj

12-13-2008, 08:27 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281 Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase full article: http://online.wsj.com/article/SB1229...googlenews_wsj __________________ Mom's treatment history (link)